“…This finding suggests that while combinations of different severities of AHs and VHs are related to brain alterations, retinal thickness may be more of a trait marker and not related to symptom severity. This idea is consistent with prior research in first episode un-medicated patients (Bernardin et al 2019;Moseley et al 2018;Thomas 1990). However, contrary to this theory, other studies have reported that retinal thickness and brain GMV reduction are affected by treatment with antipsychotics (Bordier et al 2018;Cao et al 2018;Collier et al 2014;Csaszar et al 2019;Kremlacek et al 2016;Xu et al 2016;Zmigrod et al 2016).…”
Section: Discussionsupporting
confidence: 92%
“…All four groups of FUSCHAV patients demonstrated GMV reduction, primarily located in the temporal, occipital, frontal, and parietal lobes. These findings indicate that the primary auditory and visual cortex are impaired in FUSCHAV patients (Bernardin et al 2019;Csaszar et al 2019;Moseley et al 2018). The first episode of schizophrenic patients with congenital deficiency or serious brain damage is generally severe auditory and visual hallucinations.…”
Schizophrenic patients often experience auditory hallucinations (AHs) and visual hallucinations (VHs). However, brain and retinal alterations associated with combined AHs and VHs in schizophrenic patients are unknown. This study aimed o investigate brain and retinal alterations in first episode untreated schizophrenic patients with combined AHs and VHs (FUSCHAV). FUSCHAV patients (n = 120), divided into four groups according to severity of AH and VH symptoms, were compared to healthy controls (n = 30). Gray matter volume (GMV) and global functional connectivity density (gFCD) were recorded to reflect brain structure and functional alterations. Total retinal thickness was acquired by optical coherence tomography to assess retinal impairment. The majority of FUSCHAV patients (85.8%) demonstrated both GMV reduction and gFCD increases along with retinal thinning compared to healthy controls. The severity of GMV reduction and gFCD increase differed between patient groups, ranked from highest to lowest severity as follows: severe AHs combined with severe VHs (FUSCHSASV, 20 patients), moderate AHs combined with severe VHs (FUSCHMASV, 23 patients), severe AHs combined with moderate VHs (FUSCHSAMV, 28 patients), and moderate AHs combined with moderate VHs (FUSCHMAMV, 26). Retinal impairment was similar among the four FUSCHAV groups. GMV reduction and gFCD increases in the frontal-parietal lobule show an inverted U-shaped pattern among FUSCHAV patients according to AH and VH severity, while retinal impairment remains stable among FUSCHAV groups. These findings indicate a reciprocal deterioration in auditory and visual disturbances among FUSCHAV patients.
“…This finding suggests that while combinations of different severities of AHs and VHs are related to brain alterations, retinal thickness may be more of a trait marker and not related to symptom severity. This idea is consistent with prior research in first episode un-medicated patients (Bernardin et al 2019;Moseley et al 2018;Thomas 1990). However, contrary to this theory, other studies have reported that retinal thickness and brain GMV reduction are affected by treatment with antipsychotics (Bordier et al 2018;Cao et al 2018;Collier et al 2014;Csaszar et al 2019;Kremlacek et al 2016;Xu et al 2016;Zmigrod et al 2016).…”
Section: Discussionsupporting
confidence: 92%
“…All four groups of FUSCHAV patients demonstrated GMV reduction, primarily located in the temporal, occipital, frontal, and parietal lobes. These findings indicate that the primary auditory and visual cortex are impaired in FUSCHAV patients (Bernardin et al 2019;Csaszar et al 2019;Moseley et al 2018). The first episode of schizophrenic patients with congenital deficiency or serious brain damage is generally severe auditory and visual hallucinations.…”
Schizophrenic patients often experience auditory hallucinations (AHs) and visual hallucinations (VHs). However, brain and retinal alterations associated with combined AHs and VHs in schizophrenic patients are unknown. This study aimed o investigate brain and retinal alterations in first episode untreated schizophrenic patients with combined AHs and VHs (FUSCHAV). FUSCHAV patients (n = 120), divided into four groups according to severity of AH and VH symptoms, were compared to healthy controls (n = 30). Gray matter volume (GMV) and global functional connectivity density (gFCD) were recorded to reflect brain structure and functional alterations. Total retinal thickness was acquired by optical coherence tomography to assess retinal impairment. The majority of FUSCHAV patients (85.8%) demonstrated both GMV reduction and gFCD increases along with retinal thinning compared to healthy controls. The severity of GMV reduction and gFCD increase differed between patient groups, ranked from highest to lowest severity as follows: severe AHs combined with severe VHs (FUSCHSASV, 20 patients), moderate AHs combined with severe VHs (FUSCHMASV, 23 patients), severe AHs combined with moderate VHs (FUSCHSAMV, 28 patients), and moderate AHs combined with moderate VHs (FUSCHMAMV, 26). Retinal impairment was similar among the four FUSCHAV groups. GMV reduction and gFCD increases in the frontal-parietal lobule show an inverted U-shaped pattern among FUSCHAV patients according to AH and VH severity, while retinal impairment remains stable among FUSCHAV groups. These findings indicate a reciprocal deterioration in auditory and visual disturbances among FUSCHAV patients.
“…In addition, the greater deficits observed in the V + AH group could be linked to greater visual processing deficits. Indeed, studies in patients with Parkinson disease have reported a relationship between VH and altered visual processing [34,35] and there is also evidence that patients with Parkinson disease and VH showed deficits in both visual perception and source monitoring [31]. To decipher on the contribution of visual abnormalities to the reality-monitoring deficits in patients with schizophrenia, studies investigating visual processing together with reality-monitoring are needed.…”
The presence of visual hallucinations in addition to auditory
hallucinations (V + AH) is associated with poor prognosis in patients with
schizophrenia. However, little consideration has been given to these
symptoms and their underlying cognitive bases remain unclear. Based on
cognitive models of hallucinations, we hypothesized that V + AH are
underpinned by an impairment in reality-monitoring processes. The objective
of the present study was to test whether reality-monitoring deficits were
associated with V + AH in schizophrenia. This study examined
reality-monitoring abilities in two groups of patients with schizophrenia: a
group of patients with V + AH (n = 24) and a group of patients with AH only
(n = 22). Patients with V + AH were significantly more likely to misremember
imagined words as being perceived from an external source, compared to
patients with AH only (p = 0.008, d = -0.82). In other words, V + AH
patients display a larger externalization bias than patients with AH only.
One explanation for these results could be that experiencing hallucinations
in two sensory modalities may contribute to increased vividness of mental
imagery and, in turn, lead to disruption in reality-monitoring processes.
This study helps to refine our understanding of the cognitive processes
underlying the presence of both auditory and visual hallucinations in
patients with schizophrenia.
“…These studies have generally not investigated relationships between functional retinal impairment and VH. However, a recent study (157) reported that schizophrenia patients with lifetime VH were characterized by slower signaling in bipolar cells and retinal ganglion cells compared to patients without a history of VH. This is consistent with findings of a relationship between ERG latency increases (and amplitude decreases) and VH in Parkinson's disease (158).…”
Section: Potential Retinal Contributions To Vh and Visual Distortions In Schizophreniamentioning
Schizophrenia is characterized by visual distortions in ~60% of cases, and visual hallucinations (VH) in ~25–50% of cases, depending on the sample. These symptoms have received relatively little attention in the literature, perhaps due to the higher rate of auditory vs. visual hallucinations in psychotic disorders, which is the reverse of what is found in other neuropsychiatric conditions. Given the clinical significance of these perceptual disturbances, our aim is to help address this gap by updating and expanding upon prior reviews. Specifically, we: (1) present findings on the nature and frequency of VH and distortions in schizophrenia; (2) review proposed syndromes of VH in neuro-ophthalmology and neuropsychiatry, and discuss the extent to which these characterize VH in schizophrenia; (3) review potential cortical mechanisms of VH in schizophrenia; (4) review retinal changes that could contribute to VH in schizophrenia; (5) discuss relationships between findings from laboratory measures of visual processing and VH in schizophrenia; and (6) integrate findings across biological and psychological levels to propose an updated model of VH mechanisms, including how their content is determined, and how they may reflect vulnerabilities in the maintenance of a sense of self. In particular, we emphasize the potential role of alterations at multiple points in the visual pathway, including the retina, the roles of multiple neurotransmitters, and the role of a combination of disinhibited default mode network activity and enhanced state-related apical/contextual drive in determining the onset and content of VH. In short, our goal is to cast a fresh light on the under-studied symptoms of VH and visual distortions in schizophrenia for the purposes of informing future work on mechanisms and the development of targeted therapeutic interventions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.